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medical marijuana for symptom relief receive 
little or no guidance from medical professionals.
With the increasing use of medical marijuana, 
it is time for regulations to standardize and 
monitor these substances. Currently, there is no 
state or national database to report adverse ef-
fects; the MedWatch program of the Food and 
Drug Administration is only accepting reports 
related to the approved product Epidiolex, a can-
nabidiol.5 Packaging changes to prevent such 
extremely concentrated formulations and a cen-
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Canagliflozin and Renal Outcomes in Diabetic Nephropathy
To the Editor: The CREDENCE (Canagliflozin 
and Renal Events in Diabetes with Established 
Nephropathy Clinical Evaluation) trial reported 
by Perkovic et al. (June 13 issue)1 exemplifies a 
deficiency in the pharmaceutical regulatory 
system — that is, sponsors are not required to 
ascertain whether the results of canagliflozin 
therapy and those of more cost-effective diuretic 
therapy might be similar. In this trial, cana-
glif lozin, a drug with diuretic properties, was 
administered to patients with diabetic kidney dis-
ease, nearly all of whom were receiving a renin–
angiotensin–aldosterone system (RAAS) inhibi-
tor. In the placebo group, however, fewer than 
half the patients were taking diuretics.
In a seminal study that established the reno-
protective effect of RAAS inhibition in patients 
with diabetic kidney disease, 84% of the patients 
in both the losartan and placebo groups received 
diuretics during the treatment period.2 Diuretics 
may augment the renoprotective effects of RAAS 
inhibitors by potentiating their antihypertensive 
Figure 1. Liquid Marijuana Packaging and Syringe.
The liquid marijuana product used by the patient was obtained from a local 
medical marijuana dispensary. The syringe contains the amount remaining 
after 2 days of use.
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and antiproteinuric actions.3 A clinical trial com-
paring canagliflozin added to RAAS inhibition 
with a generic thiazide diuretic added to RAAS 
inhibition in patients with diabetic kidney dis-
ease and otherwise controlled hyperglycemia 
could help to determine whether the renoprotec-
tive qualities of canagliflozin are anything more 
than those of an expensive diuretic.
Bruce R. Leslie, M.D., M.S.P.H.
Seventh Doctor Consulting 
Princeton, NJ 
seventhdoctor@ gmail . com
Leslie E. Gerwin, J.D., M.P.H.
Princeton University 
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To the Editor: The CREDENCE trial showed a 
lower risk of kidney failure and cardiovascular 
events among patients who received canagliflozin 
than among those who received placebo. The sys-
tolic blood pressure and glycated hemoglobin 
levels were higher than the recommended tar-
gets, especially in the placebo group. Previous 
studies have established that blood pressure con-
trol and diabetes control both improve renal out-
comes.1,2 To conclude that canagliflozin decreases 
the risk of kidney failure, the trial would have 
had to involve patients with proper blood pres-
sure and diabetes control that was similar in the 
two groups.
Given that canaglif lozin has diuretic proper-
ties, it is not surprising that patients in the 
canaglif lozin group had lower systolic blood 
pressure than those in the placebo group.3 Differ-
ences in medication to control blood pressure 
during the intervention were not reported in the 
trial. In fact, control of blood pressure alone 
could account for the better outcomes in the 
canagliflozin group than in the placebo group.1
The CREDENCE trial did not show the sig-
nificant increase in the rate of amputation seen 
by the CANVAS (Canaglif lozin Cardiovascular 
Assessment Study) investigators.4 The design of 
the CREDENCE trial involved the selection of pa-
tients at low risk for amputation. The exclusion 
of high-risk patients may have biased the results 
toward lower rates of amputation. In conclusion, 
we find the CREDENCE trial design and methods 
to be biased and potentially misleading.
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Washington State University Elson S. Floyd College of Medicine 
Vancouver, WA 
misreb@ peacehealth . org
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To the Editor: Ever since the outcomes of the 
CANVAS Program1 were reported, the finding of 
a significantly higher incidence of lower-limb 
amputations in the canagliflozin group than in 
the placebo group has aroused concerns. This 
finding did not occur with either empagliflozin 
or dapagliflozin.2
In the CREDENCE trial, Perkovic et al. found 
a nonsignificant but higher number of amputa-
tions among patients receiving canagliflozin at 
a dose of 100 mg daily than in those receiving 
placebo (70 vs. 63 amputations; hazard ratio, 
1.11; 95% confidence interval, 0.79 to 1.56). Al-
though the authors suggest that this finding is 
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reassuring for physicians prescribing canagliflo-
zin, we disagree.
The main differences between the CREDENCE 
trial and the CANVAS Program are that the lat-
ter had two treatment groups (canaglif lozin at 
a dose of 100 mg and canaglif lozin at a dose of 
300 mg) and a larger number of patients than 
the CREDENCE trial (10,142 vs. 4401). Different 
doses are unlikely to explain the differing results, 
since the subgroup analysis in the CANVAS Pro-
gram did not show an interaction between dose 
and amputation risk.3
However, the total number of amputations 
in the CANVAS Program was higher than that in 
the CREDENCE trial (187 vs. 133).1 Therefore, 
because of the larger number of events, safety 
outcomes in the CANVAS Program are more re-
liable, and safety issues regarding canagliflozin 
remain unresolved.
Josivan G. Lima, M.D., Ph.D. 
Marcel C. Santos, M.D. 
Breno C. Simas, M.D.
Federal University of Rio Grande do Norte 
Natal, Brazil 
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To the Editor: The CREDENCE trial showed a 
greater reduction in the estimated glomerular 
filtration rate (GFR) among patients with type 2 
diabetes and chronic kidney disease who received 
canagliflozin than among those who received 
placebo. However, because the estimated GFR 
corrects the serum creatinine level for population 
variation in muscle mass rather than for indi-
vidual variation,1 a comparison of treatments 
with respect to changes in the estimated GFR 
over time is valid only if the treatment has no ef-
fect on muscle mass.
Unfortunately, there are reasons to believe 
that canagliflozin does affect muscle mass. Cana-
gliflozin can stimulate gluconeogenesis,2 which 
uses amino acids from muscle protein for syn-
thesis of new glucose molecules. This process 
causes loss of muscle mass,3 which may explain 
the loss of lean body mass that has been observed 
in response to treatment with canaglif lozin.4 
Also, because dialysis is usually initiated accord-
ing to the estimated GFR rather than the serum 
creatinine level corrected for individual variation 
in muscle mass,5 the renoprotective effect of 
canaglif lozin described by Perkovic et al. may 
have been in whole or in part the consequence 
of loss of muscle mass. Studies or analyses that 
control for change in muscle mass may provide 
definitive answers.
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The authors reply: Leslie and Gerwin suggest 
that the benefits of canagliflozin may be due to 
a diuretic effect. Diuretics have not been shown 
to prevent kidney failure. The benefits observed 
in the CREDENCE trial were also consistent, re-
gardless of baseline diuretic use, so we think it is 
unlikely that the diuretic effect explains the bene-
fits of canagliflozin.
Isreb et al. ask whether benefits in the 
 CREDENCE trial may have resulted from between-
group differences in blood pressure or glucose 
control. Pooled analyses of intensive blood pres-
sure and glucose lowering have not shown clear 
renal benefits, so these are also unlikely explana-
tions, particularly given the modest differences 
between the two groups. The trial protocol en-
couraged investigators to deliver the best guide-
line-based care to patients according to blood 
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pressure and glucose and lipid levels. None of 
these interventions (i.e., the use of diuretics and 
intensive blood pressure and glucose lowering) 
has been shown to have benefits of the magni-
tude observed in the CREDENCE trial, despite 
multiple trials.
We disagree with the assertions by Lima et al. 
and Isreb and colleagues regarding amputation. 
Patients in the CREDENCE trial were at higher 
risk for amputation than those in the CANVAS 
Program. A history of amputation is predictive 
of subsequent amputation1 and was more com-
mon in the CREDENCE trial than in the CANVAS 
Program (in 5.3% of patients vs. 2.3% of pa-
tients).2 Also, the rate of amputation among 
patients receiving placebo in the CREDENCE 
trial was substantially higher than that among 
patients receiving placebo in the CANVAS Pro-
gram (11.2 per 1000 patient-years vs. 3.4 per 
1000 patient-years). As a result, more amputa-
tions were observed in the placebo group of the 
CREDENCE trial than in the placebo group of 
the CANVAS Program (63 vs. 47). Thus, the two 
trials had similar power to detect an increased 
risk, but the results were clearly different (P = 0.02 
for heterogeneity). We think the CREDENCE 
trial provides reassurance that the increase in 
amputation risk observed in the CANVAS Pro-
gram is very unlikely to be seen among patients 
such as those in the CREDENCE trial who re-
ceived treatment according to our protocol.
Post and colleagues ask whether weight loss 
may influence the estimated GFR values. In stud-
ies of SGLT2 inhibitors in which body composi-
tion was assessed, weight loss was driven most-
ly by decreases in fat mass, with much smaller 
decreases in lean and muscle mass.3,4 Further-
more, weight loss in the CREDENCE trial occurred 
almost entirely in the first 6 months, after which 
weight remained stable, yet the difference in the 
estimated GFR slope was observed throughout 
the full trial period. Thus, although small chang-
es in muscle mass may have a minor influence 
on the creatinine-based estimated GFR values in 
the CREDENCE trial, the magnitude of change 
in the estimated GFR slope and the time profile 
for the changes seen with canagliflozin cannot 
be explained by the small changes in weight.
We think the benefits seen with canagliflozin 
in the CREDENCE trial are clear and important.
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